| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Immune check point such as Cancer testis antigens (CTA) have emerged over the last decade as both a diagnostic marker and a therapeutic target in malignant lesions. Recently, aberrant expression of PD-1, PD-L1, NY-ESO-1 and MAGE-A4 has been reported in a variety of neoplasms. However, there is only a limited report about those expression in high grade sarcoma. The purpose of this study is to examine those expression in high-grade soft tissue sarcomas and to evaluate the relationship between CTA expression and the various clinicopathological features. In this study, it was found that PD-L1 was expressed in soft tissue tumors and the NY-ESO-1 was expressed in more than half of samples of synovial sarcoma patients. The 5-years-overall survival rates were significantly higher in high grade sarcoma patients with NY-ESO-1 positive tumors than in those with NY-ESO-1 negative. Furthermore, we showed the MAGE-A4 was expressed only in more than half of synovial sarcoma patients.
|
